Hormone Refractory Prostate Cancer and Fibroblast Growth Factor Receptor

• Published in: Breast cancer (Tokyo, Japan) Vol. 6; no. 4; pp. 320 - 324
• Main Authors: Matsubara, A, Yasumoto, H, Usui, T
• Format: Journal Article
• Language: English
• Published: Japan 01.10.1999
• ISSN: 1340-6868; 1880-4233
• DOI: 10.1007/bf02966447

In prostate cancer, a distinct series of alterations in the fibroblast growthfactor (FGF) family occurs during the progression from a hormone-dependent to independent state that disrupts communication between stroma and epithelium and results in autonomy of cancer cells. Changes include (i) loss of FGFR2IIIb, whichbinds stromal-derived FGF-7, which promotes growth, growth limitation and differentiation and (ii) activation of FGFR1, the expression of which is normally limited to stroma, along with activation of FGFs that act on FGFR1 in an autocrine manner. Transfection of the FGFR2IIIb isoform into hormone-independent prostate cancer cells not only causes growth inhibition, but also induces differentiation. However, introduction of FGFR1 by transfection in hormone-dependent prostate cancer cells accelerates their progression to malignancy. These results suggest distinct targets for therapy aimed at both inhibition of the malignant phenotype and restoration of homeostasis.